Cover Image
市場調查報告書

胃食道 (GE) 結點癌症:的開發中產品分析

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 245990
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
Back to Top
胃食道 (GE) 結點癌症:的開發中產品分析 Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015
出版日期: 2015年09月16日 內容資訊: 英文 125 Pages
簡介

胃食道結點癌症是食道和胃食道結點 (GE)產生的腺癌。主要的症狀有發音障礙和體重減少,咳嗽,吞嚥疼痛,疼痛,聲音嘶啞等。主要的易罹病素質有老齡化和超重·肥胖症,胃食道逆流症 (GERD),抽煙,飲酒等。主要的治療方法有化療和放射線治療等。

本報告提供全球各國治療食道胃結點癌症所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要 (產品概要,功能機制,研究開發 (R&D) 的發展情形),最新的產業趨勢等資訊。

簡介

  • 分析範圍

胃食道結點癌症概要

治療藥的開發

  • 胃食道結點癌症開發中產品:概要
  • 胃食道結點癌症開發中產品:比較分析

各企業開發中的胃食道結點癌症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

胃食道結點癌症治療藥:開發中的產品一覽(各企業)

胃食道結點癌症開發治療藥的企業

  • Amgen Inc.
  • Aslan Pharmaceuticals Pte. Ltd.
  • AstraZeneca Plc
  • Basilea Pharmaceutica AG
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Exelixis, Inc.
  • GlaxoSmithKline Plc
  • Hetero Drugs Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • NantKwest, Inc.
  • 小野藥品工業
  • Sorrento Therapeutics, Inc.

胃食道結點癌症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • afuresertib hydrochloride
  • AMG-211
  • avelumab
  • BAL-101553
  • cabozantinib s-malate
  • Cell Therapy to Target HER2 for Oncology
  • DKN-01
  • FS-102
  • gefitinib
  • haNK Program
  • ipilimumab
  • MK-2206
  • nimotuzumab
  • nivolumab
  • trastuzumab biosimilar
  • trastuzumab biosimilar
  • varlitinib

胃食道結點癌症治療藥:最新的藥物簡介

胃食道結點癌症治療藥:開發暫停的產品

胃食道結點癌症治療藥:開發中止的產品

胃食道結點癌症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(1件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7111IDB

Summary

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastroesophageal (GE) Junction Carcinomas Overview
  • Therapeutics Development
    • Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview
    • Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis
  • Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies
  • Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Aslan Pharmaceuticals Pte. Ltd.
    • AstraZeneca Plc
    • Basilea Pharmaceutica AG
    • Bristol-Myers Squibb Company
    • Celltrion, Inc.
    • Exelixis, Inc.
    • GlaxoSmithKline Plc
    • Hetero Drugs Limited
    • Merck & Co., Inc.
    • Merck KGaA
    • NantKwest, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Sorrento Therapeutics, Inc.
  • Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afuresertib hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMG-211 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAL-101553 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target HER2 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DKN-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FS-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gefitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • haNK Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ipilimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MK-2206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varlitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates
  • Gastroesophageal (GE) Junction Carcinomas - Dormant Projects
  • Gastroesophageal (GE) Junction Carcinomas - Discontinued Products
  • Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones
    • Featured News & Press Releases
      • Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015
  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca Plc, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Hetero Drugs Limited, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by NantKwest, Inc., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Pipeline by Sorrento Therapeutics, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H2 2015
  • Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015
  • Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top